"NVS" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonFund Update: New $223.5M $NVS stock position opened by WCM INVESTMENT MANAGEMENT, LLC - Quiver Qu...
Fund Update: New $223.5M $NVS stock position opened by WCM INVESTMENT MANAGEMENT, LLC Quiver Quantitative
NVS Stock Price, Quote & Chart | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
NVS Stock Price, Quote & Chart | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) ChartMill
Number of shareholders of Novus Holdings Ltd. – JSE:NVS - TradingView
Number of shareholders of Novus Holdings Ltd. – JSE:NVS TradingView
After March cuts, Novartis trims another 60 roles at US headquarters - Fierce Pharma
After March cuts, Novartis trims another 60 roles at US headquarters Fierce Pharma
Unveiling Novartis (NVS) Q1 outlook: Wall Street estimates for key metrics - MSN
Unveiling Novartis (NVS) Q1 outlook: Wall Street estimates for key metrics MSN
Novartis AG (NVS): One of the Best Low Risk High Growth Plays on the Market - Yahoo Finance
Novartis AG (NVS): One of the Best Low Risk High Growth Plays on the Market Yahoo Finance
NVS - Novartis AG ADR Stock Price and Quote - Finviz
Global knowledge exchange in focus as NVS welcomes students from Tokyo - Karolinska Institutet
Global knowledge exchange in focus as NVS welcomes students from Tokyo Karolinska Institutet
Novartis: Revenue Lags In Q1, Outlook Unchanged (NYSE:NVS) - Seeking Alpha
Novartis: Revenue Lags In Q1, Outlook Unchanged (NYSE:NVS) Seeking Alpha
Novartis AG (NVS) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 83/100 - GuruFocus
Novartis AG (NVS) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 83/100 GuruFocus
Proposed sale of 6,800 ADS at NVS (NYSE: NVS) reported in Form 144 - Stock Titan
Proposed sale of 6,800 ADS at NVS (NYSE: NVS) reported in Form 144 Stock Titan
Novartis AG (NVS) Stock Analysis: Evaluating Growth Potential Amidst A 4.98% Upside - DirectorsTa...
Novartis AG (NVS) Stock Analysis: Evaluating Growth Potential Amidst A 4.98% Upside DirectorsTalk Interviews
Novartis: Buy Thesis Fades Into Q1 2026 Results (Rating Downgrade) (NYSE:NVS) - Seeking Alpha
Novartis: Buy Thesis Fades Into Q1 2026 Results (Rating Downgrade) (NYSE:NVS) Seeking Alpha
NVS SMA Drug Gets CHMP Backing, Malaria Drug Wins WHO Prequalification - Yahoo Finance
NVS SMA Drug Gets CHMP Backing, Malaria Drug Wins WHO Prequalification Yahoo Finance
Jim Cramer is Optimistic About Novartis’ (NVS) Cancer Drug - Yahoo Finance
Jim Cramer is Optimistic About Novartis’ (NVS) Cancer Drug Yahoo Finance
Why Analysts Are Closely Watching Novartis AG (NVS) - Yahoo Finance
Why Analysts Are Closely Watching Novartis AG (NVS) Yahoo Finance
Novartis (NVS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Novartis (NVS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates Yahoo Finance
Exploring Analyst Estimates for Novartis (NVS) Q4 Earnings, Beyond Revenue and EPS - Yahoo Finance
Exploring Analyst Estimates for Novartis (NVS) Q4 Earnings, Beyond Revenue and EPS Yahoo Finance
Novartis (NYSE: NVS) Q1 2026 earnings dip as key drugs surge, Avidity deal closes - Stock Titan
Novartis (NYSE: NVS) Q1 2026 earnings dip as key drugs surge, Avidity deal closes Stock Titan
Novartis slips as U.S. generic erosion weighs on Q1 results (NVS:NYSE) - Seeking Alpha
Novartis slips as U.S. generic erosion weighs on Q1 results (NVS:NYSE) Seeking Alpha
Fund Update: New $108.6M $NVS stock position opened by ARROWSTREET CAPITAL, LIMITED PARTNERSHIP -...
Fund Update: New $108.6M $NVS stock position opened by ARROWSTREET CAPITAL, LIMITED PARTNERSHIP Quiver Quantitative
Novartis AG 2026 Q1 - Results - Earnings Call Presentation (NYSE:NVS) 2026-04-28 - Seeking Alpha
Novartis AG 2026 Q1 - Results - Earnings Call Presentation (NYSE:NVS) 2026-04-28 Seeking Alpha
Novartis (NVS) Reports Disappointing Q1 2026 Results Amid Generi - GuruFocus
Novartis (NVS) Reports Disappointing Q1 2026 Results Amid Generi GuruFocus
Novartis cuts 114 more jobs at New Jersey HQ as restructuring rolls on - Fierce Pharma
Novartis cuts 114 more jobs at New Jersey HQ as restructuring rolls on Fierce Pharma
Novartis (NVS) Expands Manufacturing with New Facility in North Carolina - GuruFocus
Novartis (NVS) Expands Manufacturing with New Facility in North Carolina GuruFocus
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term Yahoo Finance
Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report - Yahoo Finance
Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report Yahoo Finance
Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates Yahoo Finance
TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029 - Yahoo Finance
TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029 Yahoo Finance
Novartis AG (NVS) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amidst Core Income Challe...
Novartis (NVS) Stock Slips as Q1 Earnings Miss and CEO Flags Pricing Policy Risk - MEXC
Novartis (NVS) Stock Slips as Q1 Earnings Miss and CEO Flags Pricing Policy Risk MEXC
FDA Approves NVS' Cosentyx in Hidradenitis Suppurativa for Adolescents - Yahoo Finance
FDA Approves NVS' Cosentyx in Hidradenitis Suppurativa for Adolescents Yahoo Finance
NVS: FY26 Core Operating Income Expected to Decline Slightly - GuruFocus
NVS: FY26 Core Operating Income Expected to Decline Slightly GuruFocus
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock Backed by Strong Fundamentals - Ch...
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock Backed by Strong Fundamentals ChartMill
Here's Why Novartis (NVS) is a Strong Value Stock - Yahoo Finance
Here's Why Novartis (NVS) is a Strong Value Stock Yahoo Finance
Novartis (NVS) CEO Warns Trump Drug Pricing Policy Could Hit Global Access as Earnings Slip - Tip...
Novartis (NVS) CEO Warns Trump Drug Pricing Policy Could Hit Global Access as Earnings Slip TipRanks
NVS Contractual Recruitment 2026 Out, Apply Online - Adda247
Novartis (NVS) Reports Q1 Earnings Miss with Declining Sales - GuruFocus
Novartis (NVS) Reports Q1 Earnings Miss with Declining Sales GuruFocus
Compared to Estimates, Novartis (NVS) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Compared to Estimates, Novartis (NVS) Q3 Earnings: A Look at Key Metrics Yahoo Finance
Novartis (NVS) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance
Novartis (NVS) is an Incredible Growth Stock: 3 Reasons Why Yahoo Finance
Novartis (NVS) Earnings Date and Reports 2026 $NVS - MarketBeat
Novartis (NVS) Earnings Date and Reports 2026 $NVS MarketBeat
SA analyst upgrades/downgrades: TSLA, SMCI, NVS, KLAC - Seeking Alpha
SA analyst upgrades/downgrades: TSLA, SMCI, NVS, KLAC Seeking Alpha
Morgan Stanley Upgrades Novartis (NVS) to Overweight, Raises Price Target to CHF 110 - Yahoo Finance
Morgan Stanley Upgrades Novartis (NVS) to Overweight, Raises Price Target to CHF 110 Yahoo Finance
Why Novartis (NVS) is a Top Value Stock for the Long-Term - Yahoo Finance
Why Novartis (NVS) is a Top Value Stock for the Long-Term Yahoo Finance
Novartis AG-Sponsored ADR (NYSE:NVS): A Methodical Pick for Steady Dividend Income - ChartMill
Novartis AG-Sponsored ADR (NYSE:NVS): A Methodical Pick for Steady Dividend Income ChartMill
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Fundamentals - ChartMill
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Fundamentals ChartMill
Novartis (NYSE: NVS) grows 2025 sales 8% and boosts dividend after strong pipeline gains - Stock ...
Novartis (NYSE: NVS) grows 2025 sales 8% and boosts dividend after strong pipeline gains Stock Titan
Novartis: A Mispriced Hedge In A Crowded Equity Market - Seeking Alpha
Novartis: A Mispriced Hedge In A Crowded Equity Market Seeking Alpha
Novartis Stock: Value Price, Growth Pipeline (NYSE:NVS) - Seeking Alpha
Novartis Stock: Value Price, Growth Pipeline (NYSE:NVS) Seeking Alpha
NVS Stock Rises After FDA Grants Breakthrough Therapy Designation For Autoimmune Disorder Treatme...
NVS Stock Rises After FDA Grants Breakthrough Therapy Designation For Autoimmune Disorder Treatment Stocktwits
Novartis AG (NVS) Announces Final Two-Year Results From Phase III APPLAUSE‑IgAN Study - Yahoo Fin...
Novartis AG (NVS) Announces Final Two-Year Results From Phase III APPLAUSE‑IgAN Study Yahoo Finance
Novartis AG (NYSE:NVS) Stands Out as a Dependable Dividend Stock with Strong Fundamentals - Chart...
Novartis AG (NYSE:NVS) Stands Out as a Dependable Dividend Stock with Strong Fundamentals ChartMill
Novartis (NVS) Receives Positive CHMP Opinion for Itvisma Authorization - GuruFocus
Novartis (NVS) Receives Positive CHMP Opinion for Itvisma Authorization GuruFocus
SA analyst upgrades/downgrades: GM, UBER, UNH, NVS - Seeking Alpha
SA analyst upgrades/downgrades: GM, UBER, UNH, NVS Seeking Alpha
Novartis (NYSE: NVS) files Form 6-K on multi-tranche USD notes - Stock Titan
Novartis (NYSE: NVS) files Form 6-K on multi-tranche USD notes Stock Titan
4 stocks to watch on Friday: LLY, AMZN, NVS, UL (SP500:) - Seeking Alpha
4 stocks to watch on Friday: LLY, AMZN, NVS, UL (SP500:) Seeking Alpha
Novartis (NVS) Announces New Share Buyback Program - GuruFocus
Novartis (NVS) Announces New Share Buyback Program GuruFocus
Valve malfunction blamed for failure of Indian satellite to raise its orbit - SpaceNews
Valve malfunction blamed for failure of Indian satellite to raise its orbit SpaceNews
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Dividend Investors - ChartMill
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Dividend Investors ChartMill
Novartis AG (NVS) Advances $23B U.S. Investment Plan With New RLT Logistics Hub - Yahoo Finance
Novartis AG (NVS) Advances $23B U.S. Investment Plan With New RLT Logistics Hub Yahoo Finance
Where is Novartis AG (NVS) Headed? - Finviz
Market Update: Microsoft (MSFT), Novartis (NVS), Coca-Cola (KO) Performance Amidst Economic Conce...
Market Update: Microsoft (MSFT), Novartis (NVS), Coca-Cola (KO) Performance Amidst Economic Concerns GuruFocus
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Value Investment Case - ChartMill
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Value Investment Case ChartMill
Novartis Promises Growth Despite 'Historic' Patent Cliffs - I Broadly Agree (NYSE:NVS) - Seeking ...
Novartis Promises Growth Despite 'Historic' Patent Cliffs - I Broadly Agree (NYSE:NVS) Seeking Alpha
FDA Approves NVS' Cosentyx in Hidradenitis Suppurativa for Adolescents - Zacks Investment Research
FDA Approves NVS' Cosentyx in Hidradenitis Suppurativa for Adolescents Zacks Investment Research
Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year? Yahoo Finance
Novartis AG (NVS) Announces US FDA Approval of Itvisma® - Yahoo Finance
Novartis AG (NVS) Announces US FDA Approval of Itvisma® Yahoo Finance
Novartis (NVS) Stock Slips as Q1 Earnings Miss and CEO Flags Pricing Policy Risk - CoinCentral
Novartis (NVS) Stock Slips as Q1 Earnings Miss and CEO Flags Pricing Policy Risk CoinCentral
NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia - Yahoo Finance
NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia Yahoo Finance
Novartis AG (NVS) Stock Price Down 3.66% on Mar 11 - GuruFocus
Novartis AG (NVS) Stock Price Down 3.66% on Mar 11 GuruFocus
TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029 - Finviz
TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029 Finviz
Novartis AG (NVS): Jim Cramer Wonders Whether Its CEO Is Leaving [UPDATED] - Yahoo Finance
Novartis AG (NVS): Jim Cramer Wonders Whether Its CEO Is Leaving [UPDATED] Yahoo Finance
Novartis (NVS) Stock Falls on $2B Excellergy Acquisition to Expand Allergy Portfolio - TipRanks
Novartis (NVS) Stock Falls on $2B Excellergy Acquisition to Expand Allergy Portfolio TipRanks
Why Novartis (NVS) is a Top Value Stock for the Long-Term - Yahoo Finance
Why Novartis (NVS) is a Top Value Stock for the Long-Term Yahoo Finance
Novartis to build radioligand drug site in Texas (NVS:NYSE) - Seeking Alpha
Novartis to build radioligand drug site in Texas (NVS:NYSE) Seeking Alpha
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Financials - ChartMill
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Financials ChartMill
NVS celebrates ‘America at 250’ with concert March 19 | News, Sports, Jobs - The Express - lockha...
NVS celebrates ‘America at 250’ with concert March 19 | News, Sports, Jobs - The Express lockhaven.com
4 stocks to watch on Friday: LLY, AMZN, NVS, UL - MSN
Novartis AG (NVS) Strengthens Cardiovascular Unit with Tourmaline Bio Acquisition - Yahoo Finance
Novartis AG (NVS) Strengthens Cardiovascular Unit with Tourmaline Bio Acquisition Yahoo Finance
Novartis AG (NVS) Stock Analysis: Navigating A Steady Path With A 5.36% Potential Upside - Direct...
Novartis AG (NVS) Stock Analysis: Navigating A Steady Path With A 5.36% Potential Upside DirectorsTalk Interviews
Novartis Stock (NVS) Climbs after Paying $3B for “Mutant”- Fighting Breast Cancer Drug - TipRanks
Novartis Stock (NVS) Climbs after Paying $3B for “Mutant”- Fighting Breast Cancer Drug TipRanks
Novartis (NVS) Receives New Price Target from Morgan Stanley | N - GuruFocus
Novartis (NVS) Receives New Price Target from Morgan Stanley | N GuruFocus
Novartis: Assessing The Impact Of Entresto Generics (NYSE:NVS) - Seeking Alpha
Novartis: Assessing The Impact Of Entresto Generics (NYSE:NVS) Seeking Alpha
Novartis AG (NVS) Gets Upgraded to Overweight from Neutral by JPMorgan - Insider Monkey
Novartis AG (NVS) Gets Upgraded to Overweight from Neutral by JPMorgan Insider Monkey
Kisqali Emerges as Novartis AG (NVS) Blockbuster with Record Q2 Growth - Yahoo Finance
Kisqali Emerges as Novartis AG (NVS) Blockbuster with Record Q2 Growth Yahoo Finance
Novartis AG (NVS) Stock Analysis: Navigating Growth With A Strong 3.12% Dividend Yield - Director...
Novartis AG (NVS) Stock Analysis: Navigating Growth With A Strong 3.12% Dividend Yield DirectorsTalk Interviews
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Value Investment Case - ChartMill
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Value Investment Case ChartMill
NVS Sees Analyst Upgrade from JP Morgan to Overweight | NVS Stoc - GuruFocus
NVS Sees Analyst Upgrade from JP Morgan to Overweight | NVS Stoc GuruFocus
Novartis inks licensing deal worth up to $1.8B for oral peptide drugs - Seeking Alpha
Novartis inks licensing deal worth up to $1.8B for oral peptide drugs Seeking Alpha
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth - Zacks Investment Research
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth Zacks Investment Research
Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy...
Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy - Slideshow Seeking Alpha
Novartis: Synnovation Deal And 8% Full-Year 2025 Sales Growth (NYSE:NVS) - Seeking Alpha
Novartis: Synnovation Deal And 8% Full-Year 2025 Sales Growth (NYSE:NVS) Seeking Alpha
Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver - MarketBeat
Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver MarketBeat
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Strong Case for Dividend Investors - ChartMill
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Strong Case for Dividend Investors ChartMill
Novartis (NVS) Initiates Construction of New Biomedical Research Hub in San Diego - GuruFocus
Novartis (NVS) Initiates Construction of New Biomedical Research Hub in San Diego GuruFocus
Novartis (NVS) Reports Promising Phase III Results for Fabhalta in IgA Nephropathy - GuruFocus
Novartis (NVS) Reports Promising Phase III Results for Fabhalta in IgA Nephropathy GuruFocus
Novartis (NVS) Reports Robust Q4 Sales Growth and Pipeline Advan - GuruFocus
Novartis (NVS) Reports Robust Q4 Sales Growth and Pipeline Advan GuruFocus
Novartis (NVS) Q4 Earnings Beat Estimates Despite Revenue Miss - GuruFocus
Novartis (NVS) Q4 Earnings Beat Estimates Despite Revenue Miss GuruFocus
ISRO Cites Connector Failure in NVS-02 Loss, But Questions Linger - Orbital Today
ISRO Cites Connector Failure in NVS-02 Loss, But Questions Linger Orbital Today
Novartis (NVS) Completes Acquisition of Avidity Biosciences - GuruFocus
Novartis (NVS) Completes Acquisition of Avidity Biosciences GuruFocus